Question 1

How does evolocumab compare to my current cholesterol medication?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 clinical trial (NCT01763918). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of this treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 clinical trial (NCT01763918). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my cholesterol levels be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 clinical trial (NCT01763918). Contact the study team or your healthcare provider for specific answers.

Question 4

What are the logistics of participating, such as visit frequency and duration?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 clinical trial (NCT01763918). Contact the study team or your healthcare provider for specific answers.

Question 5

Will I receive the actual medication or a placebo?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 clinical trial (NCT01763918). Contact the study team or your healthcare provider for specific answers.

Question 6

How might this trial fit into my overall treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 clinical trial (NCT01763918). Contact the study team or your healthcare provider for specific answers.

What this study is about